This combination promotes autophagic degradation of BCR-ABL, including the T315I mutant, leading to enhanced apoptosis and inhibition of proliferation in both imatinib-sensitive and -resistant CML models. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.